0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
RSS Email Alerts
Please Wait... Processing your request... Please Wait.

News From the Food and Drug Administration | 
Rebecca Voelker, MSJ
JAMA. 2016;315(23):2514. doi:10.1001/jama.2016.7382.

Original Investigation | 
Rohan Khera, MD; Mohammad Hassan Murad, MD, MPH; Apoorva K. Chandar, MBBS, MPH; et al.
JAMA. 2016;315(22):2424-2434. doi:10.1001/jama.2016.7602.
Includes: Supplemental Content

News From the Food and Drug Administration | 
Rebecca Voelker, MSJ
JAMA. 2016;315(21):2268. doi:10.1001/jama.2016.6558.

Medical News & Perspectives | 
Bridget M. Kuehn, MSJ
JAMA. 2016;315(18):1934-1936. doi:10.1001/jama.2016.2752.

News From the Food and Drug Administration | 
Rebecca Voelker, MSJ
JAMA. 2016;315(17):1826. doi:10.1001/jama.2016.4409.

News From the Food and Drug Administration | 
Rebecca Voelker, MSJ
JAMA. 2016;315(17):1826. doi:10.1001/jama.2016.4482.

Original Investigation | 
Katherine E. Fleming-Dutra, MD; Adam L. Hersh, MD, PhD; Daniel J. Shapiro; et al.
JAMA. 2016;315(17):1864-1873. doi:10.1001/jama.2016.4151.
Includes: CME, Supplemental Content

Capitol Health Call | 
Rita Rubin, MA
JAMA. 2016;315(10):970. doi:10.1001/jama.2016.1783.

News From the Centers for Disease Control and Prevention | 
JAMA. 2016;315(10):971. doi:10.1001/jama.2016.1631.

From The Medical Letter on Drugs and Therapeutics | 
JAMA. 2016;315(5):510-511. doi:10.1001/jama.2016.0048.

Sign in

Purchase Options

• Subscribe to the journal
• Rent this article ?

A free personal account provides

• Free current issues on The JAMA Network Reader
• Free quizzes on The JAMA Network Challenge
• Commenting and personalized alerts
From The JAMA Network
JAMA Oncology
Invited Commentary  | 
Cardiac Protection in HER2-Targeted Treatment How Should We Measure New Strategies?
Ana Barac, MD, PhD; Sandra M. Swain, MD
JAMA Oncology
Original Investigation  | 
Angiotensin II–Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer A Randomized Clinical Trial
Annelies H. Boekhout, PhD; Jourik A. Gietema, MD, PhD; Bojana Milojkovic Kerklaan, PhD; et al.
JAMA Psychiatry
Original Investigation  | 
Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression A Randomized Clinical Trial
Jorge A. Quiroz, MD, MBA; Paul Tamburri, PharmD; Dennis Deptula, PhD; et al.
JAMA Cardiology
Original Investigation  | 
Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in Relation to Renal Function Over Time Insights From the ARISTOTLE Randomized ClinicalTrial
Ziad Hijazi, MD, PhD; Stefan H. Hohnloser, MD; Ulrika Andersson, MSc; et al.